Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Aaron N. Hata, Matthew J. Niederst, Hannah L. Archibald, Maria Gomez-Caraballo, Faria M. Siddiqui, Hillary E. Mulvey, Yosef E. Maruvka, Fei Ji, Hyo Eun C Bhang, Viveksagar Krishnamurthy Radhakrishna, Giulia Siravegna, Haichuan Hu, Sana Raoof, Elizabeth Lockerman, Anuj Kalsy, Dana Lee, Celina L. Keating, David A. Ruddy, Leah J. Damon, Adam S. Crystal & 10 others Carlotta Costa, Zofia Piotrowska, Alberto Bardelli, Anthony J. Iafrate, Ruslan I. Sadreyev, Frank Stegmeier, Gad Getz, Lecia V. Sequist, Anthony C. Faber, Jeffrey A. Engelman

Research output: Contribution to journalArticle

253 Citations (Scopus)

Abstract

Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR T790M gatekeeper mutation can occur either by selection of pre-existing EGFR T790M -positive clones or via genetic evolution of initially EGFR T790M -negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR T790M; treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor-resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.

Original languageEnglish
Pages (from-to)262-269
Number of pages8
JournalNature Medicine
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Epidermal Growth Factor Receptor
Tumors
Cells
Neoplasms
Clone Cells
Pharmaceutical Preparations
Drug therapy
Impact resistance
Molecular Evolution
Non-Small Cell Lung Carcinoma
Drug Therapy
Mutation
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., ... Engelman, J. A. (2016). Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine, 22(3), 262-269. https://doi.org/10.1038/nm.4040

Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. / Hata, Aaron N.; Niederst, Matthew J.; Archibald, Hannah L.; Gomez-Caraballo, Maria; Siddiqui, Faria M.; Mulvey, Hillary E.; Maruvka, Yosef E.; Ji, Fei; Bhang, Hyo Eun C; Radhakrishna, Viveksagar Krishnamurthy; Siravegna, Giulia; Hu, Haichuan; Raoof, Sana; Lockerman, Elizabeth; Kalsy, Anuj; Lee, Dana; Keating, Celina L.; Ruddy, David A.; Damon, Leah J.; Crystal, Adam S.; Costa, Carlotta; Piotrowska, Zofia; Bardelli, Alberto; Iafrate, Anthony J.; Sadreyev, Ruslan I.; Stegmeier, Frank; Getz, Gad; Sequist, Lecia V.; Faber, Anthony C.; Engelman, Jeffrey A.

In: Nature Medicine, Vol. 22, No. 3, 01.03.2016, p. 262-269.

Research output: Contribution to journalArticle

Hata, AN, Niederst, MJ, Archibald, HL, Gomez-Caraballo, M, Siddiqui, FM, Mulvey, HE, Maruvka, YE, Ji, F, Bhang, HEC, Radhakrishna, VK, Siravegna, G, Hu, H, Raoof, S, Lockerman, E, Kalsy, A, Lee, D, Keating, CL, Ruddy, DA, Damon, LJ, Crystal, AS, Costa, C, Piotrowska, Z, Bardelli, A, Iafrate, AJ, Sadreyev, RI, Stegmeier, F, Getz, G, Sequist, LV, Faber, AC & Engelman, JA 2016, 'Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition', Nature Medicine, vol. 22, no. 3, pp. 262-269. https://doi.org/10.1038/nm.4040
Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nature Medicine. 2016 Mar 1;22(3):262-269. https://doi.org/10.1038/nm.4040
Hata, Aaron N. ; Niederst, Matthew J. ; Archibald, Hannah L. ; Gomez-Caraballo, Maria ; Siddiqui, Faria M. ; Mulvey, Hillary E. ; Maruvka, Yosef E. ; Ji, Fei ; Bhang, Hyo Eun C ; Radhakrishna, Viveksagar Krishnamurthy ; Siravegna, Giulia ; Hu, Haichuan ; Raoof, Sana ; Lockerman, Elizabeth ; Kalsy, Anuj ; Lee, Dana ; Keating, Celina L. ; Ruddy, David A. ; Damon, Leah J. ; Crystal, Adam S. ; Costa, Carlotta ; Piotrowska, Zofia ; Bardelli, Alberto ; Iafrate, Anthony J. ; Sadreyev, Ruslan I. ; Stegmeier, Frank ; Getz, Gad ; Sequist, Lecia V. ; Faber, Anthony C. ; Engelman, Jeffrey A. / Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. In: Nature Medicine. 2016 ; Vol. 22, No. 3. pp. 262-269.
@article{e2042f5a37664429bccd3b8e1ba9ff22,
title = "Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition",
abstract = "Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR T790M gatekeeper mutation can occur either by selection of pre-existing EGFR T790M -positive clones or via genetic evolution of initially EGFR T790M -negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR T790M; treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor-resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.",
author = "Hata, {Aaron N.} and Niederst, {Matthew J.} and Archibald, {Hannah L.} and Maria Gomez-Caraballo and Siddiqui, {Faria M.} and Mulvey, {Hillary E.} and Maruvka, {Yosef E.} and Fei Ji and Bhang, {Hyo Eun C} and Radhakrishna, {Viveksagar Krishnamurthy} and Giulia Siravegna and Haichuan Hu and Sana Raoof and Elizabeth Lockerman and Anuj Kalsy and Dana Lee and Keating, {Celina L.} and Ruddy, {David A.} and Damon, {Leah J.} and Crystal, {Adam S.} and Carlotta Costa and Zofia Piotrowska and Alberto Bardelli and Iafrate, {Anthony J.} and Sadreyev, {Ruslan I.} and Frank Stegmeier and Gad Getz and Sequist, {Lecia V.} and Faber, {Anthony C.} and Engelman, {Jeffrey A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/nm.4040",
language = "English",
volume = "22",
pages = "262--269",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

AU - Hata, Aaron N.

AU - Niederst, Matthew J.

AU - Archibald, Hannah L.

AU - Gomez-Caraballo, Maria

AU - Siddiqui, Faria M.

AU - Mulvey, Hillary E.

AU - Maruvka, Yosef E.

AU - Ji, Fei

AU - Bhang, Hyo Eun C

AU - Radhakrishna, Viveksagar Krishnamurthy

AU - Siravegna, Giulia

AU - Hu, Haichuan

AU - Raoof, Sana

AU - Lockerman, Elizabeth

AU - Kalsy, Anuj

AU - Lee, Dana

AU - Keating, Celina L.

AU - Ruddy, David A.

AU - Damon, Leah J.

AU - Crystal, Adam S.

AU - Costa, Carlotta

AU - Piotrowska, Zofia

AU - Bardelli, Alberto

AU - Iafrate, Anthony J.

AU - Sadreyev, Ruslan I.

AU - Stegmeier, Frank

AU - Getz, Gad

AU - Sequist, Lecia V.

AU - Faber, Anthony C.

AU - Engelman, Jeffrey A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR T790M gatekeeper mutation can occur either by selection of pre-existing EGFR T790M -positive clones or via genetic evolution of initially EGFR T790M -negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR T790M; treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor-resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.

AB - Although mechanisms of acquired resistance of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers to EGFR inhibitors have been identified, little is known about how resistant clones evolve during drug therapy. Here we observe that acquired resistance caused by the EGFR T790M gatekeeper mutation can occur either by selection of pre-existing EGFR T790M -positive clones or via genetic evolution of initially EGFR T790M -negative drug-tolerant cells. The path to resistance impacts the biology of the resistant clone, as those that evolved from drug-tolerant cells had a diminished apoptotic response to third-generation EGFR inhibitors that target EGFR T790M; treatment with navitoclax, an inhibitor of the anti-apoptotic factors BCL-xL and BCL-2 restored sensitivity. We corroborated these findings using cultures derived directly from EGFR inhibitor-resistant patient tumors. These findings provide evidence that clinically relevant drug-resistant cancer cells can both pre-exist and evolve from drug-tolerant cells, and they point to therapeutic opportunities to prevent or overcome resistance in the clinic.

UR - http://www.scopus.com/inward/record.url?scp=84978619027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978619027&partnerID=8YFLogxK

U2 - 10.1038/nm.4040

DO - 10.1038/nm.4040

M3 - Article

VL - 22

SP - 262

EP - 269

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 3

ER -